Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.
暂无分享，去创建一个
K. Tarte | R. Houot | R. Bouabdallah | P. Feugier | H. Tilly | C. Haioun | L. Ysebaert | F. Morschhauser | G. Damaj | C. Thieblemont | E. Gyan | G. Cartron | D. Sibon | H. Ghesquières | S. Gouill | C. Laurent | C. Herbaux | S. Guidez | N. Morineau | R. Gressin